Circulation Research, Vol 53, 731-739, Copyright © 1983 by American Heart Association

ARTICLES

Effect of sulfinpyrazone on homocysteine-induced endothelial injury and arteriosclerosis in baboons

LA Harker, JM Harlan and R Ross

The effect of sulfinpyrazone on endothelial injury induced by homocysteine has been studied both in vitro, using cultured human umbilical vein endothelial cells, and in vivo, using a primate model of homocysteine-induced arteriosclerosis. Oral sulfinpyrazone (250 mumol/kg body weight per day in three divided doses) in eight chronically homocystinemic baboons (0.14 +/- 0.04 mM plasma homocystine) decreased the extent of aortic endothelial injury as measured morphometrically by silver staining techniques, compared with six untreated comparably homocystinemic animals (denuded surface averaged 0.5% with range 0-2.1 vs 7.7 +/- 1.6%, respectively; P less than 0.001). Sulfinpyrazone therapy to homocystinemic baboons also normalized platelet survival and turnover measurements (5.1 +/- 0.4 days and 70,000 +/- 11,000 platelets/microliter per day vs. 2.8 +/- 0.6 days and 179,000 +/- 19,000 platelets/microliter per day in untreated homocystinemic controls; P less than 0.001). Sulfinpyrazone therapy also reduced the size and frequency of homocysteine-induced intimal lesion formation (P less than 0.001). Although sulfinpyrazone reduced the amount of specific 51Cr release from cultured human umbilical vein endothelial cells induced by 10 mM homocysteine after 24 hours of co- incubation, no effect was observed in assays of endothelial cell detachment when sulfinpyrazone (10(-5) M) or its thioether metabolite were pre- or co-incubated during 24 hours with homocysteine (2.5-10 mM). These data suggest that sulfinpyrazone may protect endothelial cells from injury in vivo by some apparently indirect mechanism.

This article has been cited by other articles:

				C. Sucker, C. Kurschat, F. Farokhzad, G. R. Hetzel, B. Grabensee, B. Maruhn-Debowski, R. Loncar, R. E. Scharf, and R. B. Zotz The TT Genotype of the C677T Polymorphism in the Methylentetrahydrofolate Reductase as a Risk Factor in Thrombotic Microangiopathies: Results From a Pilot Study Clinical and Applied Thrombosis/Hemostasis, June 1, 2009; 15(3): 283 - 288. [Abstract] [PDF]

				C. Held, G. Sumner, P. Sheridan, M. McQueen, S. Smith, G. Dagenais, S. Yusuf, and E. Lonn Correlations between plasma homocysteine and folate concentrations and carotid atherosclerosis in high-risk individuals: baseline data from the Homocysteine and Atherosclerosis Reduction Trial (HART) Vascular Medicine, November 1, 2008; 13(4): 245 - 253. [Abstract] [PDF]

				J. F. E. Mann, P. Sheridan, M. J. McQueen, C. Held, J. M. O. Arnold, G. Fodor, S. Yusuf, E. M. Lonn, and on behalf of the HOPE-2 investigators Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease--results of the renal Hope-2 study Nephrol. Dial. Transplant., February 1, 2008; 23(2): 645 - 653. [Abstract] [Full Text] [PDF]

				J. A. McMahon, C. M. Skeaff, S. M. Williams, and T. J. Green Lowering Homocysteine with B Vitamins Has No Effect on Blood Pressure in Older Adults J. Nutr., May 1, 2007; 137(5): 1183 - 1187. [Abstract] [Full Text] [PDF]

				Q. H. Meng, G. Yang, W. Yang, B. Jiang, L. Wu, and R. Wang Protective Effect of Hydrogen Sulfide on Balloon Injury-Induced Neointima Hyperplasia in Rat Carotid Arteries Am. J. Pathol., April 1, 2007; 170(4): 1406 - 1414. [Abstract] [Full Text] [PDF]

				H. Jakubowski Pathophysiological Consequences of Homocysteine Excess J. Nutr., June 1, 2006; 136(6): 1741S - 1749S. [Abstract] [Full Text] [PDF]

				The Heart Outcomes Prevention Evaluation (HOPE) 2 Homocysteine Lowering with Folic Acid and B Vitamins in Vascular Disease N. Engl. J. Med., April 13, 2006; 354(15): 1567 - 1577. [Abstract] [Full Text] [PDF]

				R. Ullegaddi, H. J. Powers, and S. E. Gariballa Antioxidant Supplementation With or Without B-Group Vitamins After Acute Ischemic Stroke: A Randomized Controlled Trial JPEN J Parenter Enteral Nutr, March 1, 2006; 30(2): 108 - 114. [Abstract] [Full Text] [PDF]

				H. Tan, X. Jiang, F. Yang, Z. Li, D. Liao, J. Trial, M. J. Magera, W. Durante, X. Yang, and H. Wang Hyperhomocysteinemia inhibits post-injury reendothelialization in mice Cardiovasc Res, January 1, 2006; 69(1): 253 - 262. [Abstract] [Full Text] [PDF]

				S.-J. Lee, K.-M. Kim, S. Namkoong, C.-K. Kim, Y.-C. Kang, H. Lee, K.-S. Ha, J.-A Han, H.-T. Chung, Y.-G. Kwon, et al. Nitric Oxide Inhibition of Homocysteine-induced Human Endothelial Cell Apoptosis by Down-regulation of p53-dependent Noxa Expression through the Formation of S-Nitrosohomocysteine J. Biol. Chem., February 18, 2005; 280(7): 5781 - 5788. [Abstract] [Full Text] [PDF]

				M. Bosch-Marce, R. Pola, A. B Wecker, M. Silver, A. Weber, C. Luedemann, C. Curry, T. Murayama, M. Kearney, Y.-s. Yoon, et al. Hyperhomocyst(e)inemia impairs angiogenesis in a murine model of limb ischemia Vascular Medicine, February 1, 2005; 10(1): 15 - 22. [Abstract] [PDF]

				K. Kramer, E. O. Harrington, Q. Lu, R. Bellas, J. Newton, K. L. Sheahan, and S. Rounds Isoprenylcysteine Carboxyl Methyltransferase Activity Modulates Endothelial Cell Apoptosis Mol. Biol. Cell, March 1, 2003; 14(3): 848 - 857. [Abstract] [Full Text] [PDF]

				U. Lim and P. A. Cassano Homocysteine and Blood Pressure in the Third National Health and Nutrition Examination Survey, 1988-1994 Am. J. Epidemiol., December 15, 2002; 156(12): 1105 - 1113. [Abstract] [Full Text] [PDF]

				O. Stanger, H.-J. Semmelrock, W. Wonisch, U. Bos, E. Pabst, and T. C. Wascher Effects of Folate Treatment and Homocysteine Lowering on Resistance Vessel Reactivity in Atherosclerotic Subjects J. Pharmacol. Exp. Ther., October 1, 2002; 303(1): 158 - 162. [Abstract] [Full Text] [PDF]

				G. BESSEDE, C. MIGUET, P. GAMBERT, D. NEEL, and G. LIZARD Efficiency of homocysteine plus copper in inducing apoptosis is inversely proportional to {gamma}-glutamyl transpeptidase activity FASEB J, September 1, 2001; 15(11): 1927 - 1940. [Abstract] [Full Text] [PDF]

				M. Weger, O. Stanger, H. Deutschmann, M. Simon, W. Renner, O. Schmut, J. Semmelrock, and A. Haas Hyperhomocyst(e)inaemia, but not MTHFR C677T mutation, as a risk factor for non-arteritic ischaemic optic neuropathy Br. J. Ophthalmol., July 1, 2001; 85(7): 803 - 806. [Abstract] [Full Text] [PDF]

				A. A.-B. Badawy Moderate alcohol consumption as a cardiovascular risk factor: the role of homocysteine and the need to re-explain the 'French Paradox' Alcohol Alcohol., May 1, 2001; 36(3): 185 - 188. [Full Text] [PDF]

				J. K. Kerzee and K. S. Ramos Activation of c-Ha-ras by Benzo(a)pyrene in Vascular Smooth Muscle Cells Involves Redox Stress and Aryl Hydrocarbon Receptor Mol. Pharmacol., July 1, 2000; 58(1): 152 - 158. [Abstract] [Full Text]

				J. Y. Jeremy, D. Rowe, A. M. Emsley, and A. C. Newby Nitric oxide and the proliferation of vascular smooth muscle cells Cardiovasc Res, August 15, 1999; 43(3): 580 - 594. [Full Text] [PDF]

				P. A. Outinen, S. K. Sood, S. I. Pfeifer, S. Pamidi, T. J. Podor, J. Li, J. I. Weitz, and R. C. Austin Homocysteine-Induced Endoplasmic Reticulum Stress and Growth Arrest Leads to Specific Changes in Gene Expression in Human Vascular Endothelial Cells Blood, August 1, 1999; 94(3): 959 - 967. [Abstract] [Full Text] [PDF]

				J. C. Chambers, A. McGregor, J. Jean-Marie, O. A. Obeid, and J. S. Kooner Demonstration of Rapid Onset Vascular Endothelial Dysfunction After Hyperhomocysteinemia : An Effect Reversible With Vitamin C Therapy Circulation, March 9, 1999; 99(9): 1156 - 1160. [Abstract] [Full Text] [PDF]

				R. C. Austin, S. K. Sood, A. M. Dorward, G. Singh, S. G. Shaughnessy, S. Pamidi, P. A. Outinen, and J. I. Weitz Homocysteine-dependent Alterations in Mitochondrial Gene Expression, Function and Structure. HOMOCYSTEINE AND H2O2 ACT SYNERGISTICALLY TO ENHANCE MITOCHONDRIAL DAMAGE J. Biol. Chem., November 13, 1998; 273(46): 30808 - 30817. [Abstract] [Full Text] [PDF]

				G. N. Welch and J. Loscalzo Homocysteine and Atherothrombosis N. Engl. J. Med., April 9, 1998; 338(15): 1042 - 1050. [Full Text] [PDF]

				M. H. Moghadasian, B. M. McManus, and J. J. Frohlich Homocyst(e)ine and Coronary Artery Disease: Clinical Evidence and Genetic and Metabolic Background Arch Intern Med, November 10, 1997; 157(20): 2299 - 2308. [Abstract] [PDF]

				A. Majors, L. A. Ehrhart, and E. H. Pezacka Homocysteine as a Risk Factor for Vascular Disease : Enhanced Collagen Production and Accumulation by Smooth Muscle Cells Arterioscler. Thromb. Vasc. Biol., October 1, 1997; 17(10): 2074 - 2081. [Abstract] [Full Text]

				A. D'Angelo and J. Selhub Homocysteine and Thrombotic Disease Blood, July 1, 1997; 90(1): 1 - 11. [Full Text] [PDF]

				P. N. Hopkins, L. L. Wu, J. Wu, S. C. Hunt, B. C. James, G. M. Vincent, and R. R. Williams Higher Plasma Homocyst(e)ine and Increased Susceptibility to Adverse Effects of Low Folate in Early Familial Coronary Artery Disease Arterioscler. Thromb. Vasc. Biol., September 1, 1995; 15(9): 1314 - 1320. [Abstract] [Full Text]

				C. Zhang, Y. Cai, M. T. Adachi, S. Oshiro, T. Aso, R. J. Kaufman, and S. Kitajima Homocysteine Induces Programmed Cell Death in Human Vascular Endothelial Cells through Activation of the Unfolded Protein Response J. Biol. Chem., September 14, 2001; 276(38): 35867 - 35874. [Abstract] [Full Text] [PDF]